⌘K
Loading ticker…
As of 2026-08-24, ABVC BioPharma, Inc. Common Stock (ABVC) has a 3-month relative strength percentile of 16 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 33. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.4%, relative volume 0.68×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
ABVC is in a stage 4 downtrend, week 6. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -32.0% / -47.6%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
ABVC appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $185K notional.
Held by 1 ETFs · $185K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $185K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ABVC Jan avg: 7.23% median: 5.14% win: 50% σ: 19.77% n: 4 2022-04-12 → 2026-07-31 | ABVC Feb avg: -7.51% median: -14.18% win: 25% σ: 29.50% n: 4 2022-04-12 → 2026-07-31 | ABVC Mar avg: 8.08% median: 2.33% win: 50% σ: 33.50% n: 4 2022-04-12 → 2026-07-31 | ABVC Apr avg: -0.46% median: 0.00% win: 40% σ: 7.07% n: 5 2022-04-12 → 2026-07-31 | ABVC May avg: 2.50% median: 0.01% win: 60% σ: 30.86% n: 5 2022-04-12 → 2026-07-31 | ABVC Jun avg: 0.37% median: -2.53% win: 40% σ: 41.12% n: 5 2022-04-12 → 2026-07-31 | ABVC Jul avg: -23.66% median: -36.08% win: 40% σ: 26.33% n: 5 2022-04-12 → 2026-07-31 | ABVC Aug avg: 3.14% median: 2.29% win: 50% σ: 43.86% n: 4 2022-04-12 → 2026-07-31 (current) | ABVC Sep avg: -6.22% median: -5.84% win: 50% σ: 12.81% n: 4 2022-04-12 → 2026-07-31 | ABVC Oct avg: -5.00% median: -3.39% win: 50% σ: 9.47% n: 4 2022-04-12 → 2026-07-31 | ABVC Nov avg: -2.16% median: -1.01% win: 50% σ: 16.47% n: 4 2022-04-12 → 2026-07-31 | ABVC Dec avg: -8.35% median: -11.67% win: 25% σ: 14.22% n: 4 2022-04-12 → 2026-07-31 |